Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.72 EUR
Change Today +0.02 / 2.86%
Volume 1.2M
ALNEV On Other Exchanges
EN Paris
As of 11:35 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

neovacs (ALNEV) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/17/14 - €3.87
52 Week Low
09/29/15 - €0.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOVACS (ALNEV)

Related News

No related news articles were found.

neovacs (ALNEV) Related Businessweek News

No Related Businessweek News Found

neovacs (ALNEV) Details

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune and inflammatory diseases, and cancer in France. The company’s product pipeline comprises IFNa-Kinoid, an anti interferon alpha therapeutic vaccine developed for the treatment of lupus; and TNF-Kinoid, an anti-TNF immunotherapy for rheumatoid arthritis and Crohn’s disease. Neovacs S.A. is based in Paris, France.

17 Employees
Last Reported Date: 03/23/15

neovacs (ALNEV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €182.1K
Compensation as of Fiscal Year 2014.

neovacs (ALNEV) Key Developments

Neovacs Announces Earnings Results for the Six Month Ended June 30, 2015

Neovacs announced earnings results for the six month ended June 30,2015. For the period, the company reported revenue of EUR 94,000 against EUR 57,000 a year ago. Operating loss was EUR 5,620,000 against EUR 4,518,000 a year ago. Pretax loss was EUR 5,825,000 against EUR 4,582,000 a year ago. Net loss was EUR 4,870,000 against EUR 3,861,000 a year ago.

NEOVACS Initiates Phase IIb Trial of IFN KINOID for the Treatment of Lupus

NEOVACS announced it has begun enrolling patients in IFN-K-002, a Phase IIb clinical trial to evaluate the efficacy of IFN Kinoid, Neovacs' lead active immunotherapy product candidate, to treat Systemic Lupus Erythematosus (SLE or lupus). Phase IIB trial design for IFN-K-002 in SLE: IFN-K-002 is a double-blind, randomized, placebo-controlled, multi-center Phase IIb clinical study to assess the biological and clinical efficacy of IFN Kinoid in patients suffering from SLE. The study aims to enroll 166 patients in Europe, Asia and Latin America. The co-primary endpoints for the trial are biogical efficacy and clinical efficacy nine months after first treatment with IFN Kinoid. Biological efficacy is defined as IFN signature neutralization, while clinical efficacy will be measured by the BILAG-based Composite Lupus Assessment (BICLA) response. Results of the clinical trial are expected in the first quarter of 2017.

Neovacs Presents Data from the Phase I/II Clinical Trial of IFNa-Kinoid

Stellar Biotechnologies Inc. announced that its partner Neovacs recently presented promising extended follow-up data from the Phase I/IIa clinical trial of IFNa-Kinoid, which is being evaluated for the treatment of Systemic Erythematosus Lupus. Stellar KLH is a primary component of Neovacs' proprietary immunotherapy Kinoid technology and is the carrier molecule in Neovacs' IFNa-Kinoid. Stellar and Neovacs recently entered into an expanded supply agreement to meet Neovacs' clinical and commercial requirements for KLH. Neovacs presented the promising extended follow-up data during Lupus 2015, the 11th International Congress on SLE, held September 2-6, 2015 in Vienna, Austria. The new data was collected as part of the Phase I/IIa extended follow-up study of six IFNa-Kinoid-treated patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNEV:FP €0.72 EUR +0.02

ALNEV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALNEV.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALNEV Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOVACS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at